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Abstract  
This study appraises the effectiveness and cost-effectiveness of consumption of plant sterol-enriched margarine-
type spreads for the prevention of cardiovascular disease (CVD) in people with hypercholesterolemia in 
England, compared to a normal diet. A nested Markov model was employed using the perspective of the British 
National Health Service (NHS). Effectiveness outcomes were the 10-year CVD risk of individuals with mild (4 
to 6 mmol/l) and high (above 6mmol/l) cholesterol by gender and age groups (45-54, 55-64, 65-74, 75-85 
years); CVD events avoided and QALY gains over 20 years.  This study found that daily consumption of 
enriched spread reduces CVD risks more for men and older age groups. Assuming 50% compliance, 69 CVD 
events per 10,000 men and 40 CVD events per 10,000 women would be saved over 20 years. If the NHS pays 
the excess cost of enriched spreads, for the high cholesterol group, the probability of enriched spreads being cost 
effective is 100% for men aged over 64 years and women over 74, at £20,000 / QALY threshold.  Probabilities 
of cost effectiveness are lower at younger ages and with mildly elevated cholesterol. If consumers bear the full 
cost of enriched spread, NHS savings arise from reduced CVD events.  
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Introduction  
Raised total or low-density-lipoprotein cholesterol (LDL-c) is a major risk factor predisposing an individual to 
cardiovascular disease (CVD) which can be modified by various prevention programmes, such as changes in 
diet. Plant sterols and stanols (a saturated subgroup of sterols), hereafter referred to collectively as plant sterols, 
are plant equivalents of cholesterol with a very similar molecular structure [1].  They are found naturally in fruit, 
vegetables, nuts, seeds, grains and legumes and prevent the absorption of cholesterol into the bloodstream, but 
are unlikely to be consumed in sufficient quantities to reduce cholesterol levels [2-4]. Research has shown that 
adding plant sterols into the daily diet can substantially enhance the cholesterol-lowering effects of diet change 
[2-5].  Functional foods enriched with plant sterols, including margarine-type spreads, mayonnaise and salad 
dressing, and dairy products (milk, yogurt, cheese), have been shown to achieve a beneficial effect on the serum 
lipid profile of the consumer [6].  
 
Although the effectiveness of plant sterols in reducing LDL-c has been verified in a number of studies [2, 3, 7-
13], evidence on whether use of plant sterols is a cost-effective preventive strategy for reducing CVD risks is 
limited. To date, only four modelling studies have been identified but their findings may not be applicable to the 
United Kingdom (UK) context [14-17]. Three of these studies based their CVD risk estimations on the 
Framingham equation, which has been shown to overestimate CVD risks for the UK population and is no longer 
recommended by the National Institute of Health and Clinical Excellence (NICE) [18, 19]. Moreover, health 
states in some studies are simplified for the convenience of the analysis [14, 16]. Also, it is instructive to look at 
the cost effectiveness separately for different age and gender groups and at different compliance levels.   
 
In this manuscript, a nested Markov model is employed to assess the effectiveness and cost-effectiveness of 
plant sterol– enriched functional foods for the prevention of CVD disease in the English population with 
hypercholesterolemia, when compared to a normal diet (no plant sterol– enriched functional foods). The 
analysis takes the perspective of the British National Health Service (NHS), and considers costs borne by 
consumers for the purchase of functional foods. Health outcomes are represented by CVD events, mortality and 
quality adjusted life years (QALYs). Cost effectiveness is defined by the NICE threshold of between £20,000 
and £30,000 per QALY gained [20]. 
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Methods 
Model structure 
A decision analytical model was used to synthesise epidemiological, clinical and economic data to appraise the 
effectiveness and cost-effectiveness of plant sterol- enriched functional foods in the prevention of CVD in 
England.  A nested Markov model structure, which allows the occurrence of both primary and secondary CVD 
events, was derived from a model used previously for a health technology assessment of the impact of statins 
[21].  All individuals start in the event free (EF) health state. During each annual cycle of the model, individuals 
(depending on their risk) either remain EF or have a primary event and enter one of the event health states: 
stable angina, unstable angina, non fatal myocardial infarction (MI), transient ischaemic attack (TIA), non fatal 
stroke, or death (either due to CVD or other causes). In each subsequent cycle, individuals in a non-fatal CVD 
event health state may move to a secondary event state, as shown in Table 1.  
 
<Table 1 about here> 
 
Population 
The analysis focused on individuals aged 45 and above with baseline total cholesterol level >= 4 mmol/l [22].  
Based on evidence in a recent meta-analysis, it was assumed that plant sterols are a primary prevention strategy 
and effective only for people in the EF state [4]. Hence, those with a history of CVD were excluded. The 
baseline cohort was drawn from the Health Survey for England (HSE) 2011, an annual survey conducted by the 
Health and Social Care Information Centre that uses random samples of the population living in private 
households to gather information about the nation’s health. In particular, the HSE 2011 focused on CVD and 
gathered information on an individual’s risk factors, including cholesterol level, CVD history and other relevant 
health and demographic variables. Data from the HSE 2011have been used to model CVD risks in various 
health economic studies [23, 24].  
 
Two clinical scenarios were considered: individuals with cholesterol levels between 4mmol/l and 6mmol/l 
(mildly elevated cholesterol population) and those with cholesterol levels above 6mmol/l (high cholesterol 
population)[22]. For each scenario, the population was modelled separately by gender and age group (45-54, 55-
64, 65-74, 75-85 years).  The age range was determined by the QRISK2 function (www.qrisk.org), which was 
used to predict CVD risks, and which only extends to 85 years.  
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Estimation of CVD risk and other cause mortality 
The primary estimation of CVD risk for the study population was based on the QRISK2 equation (QRISK2-
2014). Recommended by NICE, QRISK2 is a new CVD risk prediction tool which provides a 10-year CVD risk 
estimation for the UK population (www.qrisk.org) [25]. It is a validated tool and has been used in various 
clinical studies [18, 19]. QRISK2 predicts CVD risks based on a wide range of risk factors including age, 
systolic blood pressure, smoking status, ethnicities, ratio of total serum cholesterol to high density lipoprotein, 
body mass index, family history of coronary heart disease in first degree relative, body mass index (BMI), 
Townsend deprivation score, treated hypertension, and diagnosis of rheumatoid arthritis, atrial fibrillation, type 
2 diabetes, and chronic renal disease.  
 
The 10-year individual risk prediction provided by QRISK2 was converted to a 1-year risk for each gender and 
age subgroups. The conversion is based on published and validated algorithms [16, 26]. The QRISK2 tool 
indicates the probability of a CVD event occurring, but not the type of event. The distribution of types of events 
within groups, and the transition probabilities to model the number of people moving from any particular health 
state to another over subsequent cycles, were based on the probabilities in a study conducted by Ward et al. [21]. 
The percentage of people dying from non-CVD causes was accounted for using age and gender specific 
mortality rates derived from the life table in the 2011 Census of England and Wales [27].  Annual risks of non-
CVD deaths were estimated from the causes of death register by subtracting the fraction of deaths due to CVD 
causes from the total mortality.  
 
Clinical effectiveness of plant sterols on cholesterol lowering 
The dose-response relationship for the cholesterol lowering effect of plant sterols has been explored in a number 
of meta-analyses [2, 7, 9]. It is suggested that the LDL-c-lowering effect starts at intakes of 2–3g/day with little 
additional benefit at higher intakes [1, 7]. It is also suggested that incorporating higher amounts of plant sterols 
into foods is technically unrealistic [28, 29]. Several health authorities include 3g/day plant sterols from 
enriched foods as part of their diet and lifestyle guidelines in the management of hypercholesterolemia [30, 31]. 
Therefore, this study used 3g/day as the dose value for plant sterols in the model.  
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A literature search was undertaken to identify the clinical effectiveness of plant sterols. A scientific opinion by 
the European Food Safety Authority (EFSA) suggested that an intake of plant sterols of 3g/day (2.6g to 3.4g) 
reduced the LDL-c levels effectively by 11.2-11.4 % (95% CI: 9.8 – 13.0), and that the minimum duration 
required to achieve the maximum effect is two to three weeks [4]. The conclusions of the effect size were 
consistent with other findings [2, 7]. The most recent clinical evidence (up to 2014) is provided by the meta-
analysis of 129 studies by Ras et al., [9] concluding that intakes of approximately 3g/day (plant sterols) led to an 
average LDL-cholesterol-lowering effect of 12%, and this was used as the basis for the modelling. In the 
absence of evidence for the time course of intervention effects, it was assumed that the protective effect of plant 
sterols continues, providing minimum intakes are maintained.  
 
Impact of plant sterols on relative risk 
The 10-year CVD risk was re-calculated for each individual in the study population using the QRISK2 
assessment tool, and grouped by gender and age (as described above), assuming a 12% reduction to total 
cholesterol or LDL-c level caused by consuming 3g/day of plant sterols. Relative risk (RR) was calculated as 
the ratio of the probability of a CVD event occurring with consumption of plant sterols to the probability of the 
event occurring in the non-exposed (normal diet) condition, for each gender and age group. Relative risks were 
used in the simulation, with standard errors of RRs taken into account to reduce parameter uncertainties. In this 
way the difference in number of events between the functional food and normal diet conditions, and specifically 
the number of events avoided by sterol consumption, were identified.  
 
Costs of health states and functional foods 
One output of the model was annual numbers of individuals in different health states to which unit costs of 
treatment were applied. The cost of an event was included in the year in which it occurred, and a maintaining 
cost was applied in subsequent years. Costs of health states were largely obtained using 2014 NHS reference 
costs [32]. Where cost information was not available, costs from a published health technology evaluation of 
statins were used [21].  Information on the cost of health states can be found in Appendix 1.  
 
Commonly available foods enriched with sterols include margarine type spreads, yogurt and milk. The analysis 
was based on spread, as this is the product that enables the required dose of plant sterols (3 g per day) to be 
consumed at the least cost. Margarine type spreads are common items in the diet of the British population with 
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median consumption in adults around 40 g per day [33], which is sufficient to ensure an intake of 3g of sterols 
(Appendix 2).  The costs of products were obtained from the websites of three national supermarket chains in 
the UK in April 2015, with the supermarket own brand used for the non sterol enriched spread. Unit costs were 
the same across retailers for each product. Calculation of food costs can be found in Appendix 2.  
 
Quality adjusted life years (QALYs) 
Utility estimates for health states were derived from various sources following a review of the literature that 
focussed on UK based studies and use of the preference based utility instrument, the EQ-5D, which is the 
recommended instrument for measuring QALYs [34-36]. Health utilities used in the analysis can be found in 
Appendix 1. These utility values were applied to annual health states for individuals, and a mean value 
calculated.   
 
Main analysis 
The baseline population was described using summary statistics. CVD risks and RRs for the normal diet group 
and plant sterol condition were compared.  A cost-effectiveness analysis was then conducted from the NHS 
perspective. The price of spread enriched with plant sterols is higher than that of non-enriched spread and this 
may discourage purchase. Therefore, in the base case, it was assumed that the NHS would subsidise the cost 
difference between the supermarket own brand non enriched spread (£54.10 pa) and the manufacturer brand 
plant sterol spread (£111.04 pa), i.e. £56.94 pa, for each of the 20 years of the modelling (Appendix 1). Two 
compliance rates—10% and 50%, based around pessimistic and ideal levels identified in a Canadian study—
were explored [17].  The modelling was conducted over 20 years until the average age of the baseline cohort 
reached the life expectancy of the UK population (85 years). In line with NICE recommendations for health 
technology assessments, a discount rate of 3.5% was used for both costs and utilities [37].  
 
The number of events avoided by consuming plant sterols over the modelling period was calculated by a 
deterministic model. Incremental costs, incremental QALYs, and the incremental cost effectiveness ratios 
(ICERs) were then calculated for each gender and age group. Incremental costs from the plant sterol diet, 
compared to the normal diet, were calculated as the cost of the NHS subsidy for the spread over the 20 year 
period less any treatment cost savings from reduced CVD events. Incremental QALYs are the difference in 
QALYs between the plant sterol group and the normal diet group. ICERs show the cost per QALY gained when 
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a diet enriched with plant sterols is followed, rather than a diet without the functional food. Uncertainty around 
point estimates in the cost effectiveness analysis was examined using probabilistic sensitivity analysis (PSA), 
and Cost Effectiveness Acceptability Curves (CEAC) were plotted. For each age and gender group, a 2nd order 
Monte Carlo simulation using the probabilistic parameters based on 5,000 replications was carried out [26].  
 
Sensitivity analysis 
Four sets of sensitivity analyses were conducted. First, a one-way sensitivity analysis related to the assumed 
clinical efficacy of plant sterols was conducted using the estimated upper (13.3%) and lower (10.7%) limits of 
95% confidence intervals around the average LDL reduction level of 12% in the paper [9].  Second, we used 10 
year as the time horizon to re-calculate the ICER. Third, it was assumed that the NHS pays the full food costs, 
and the compliance level was 50%. Lastly, it was assumed that individuals were responsible for the full costs of 
the plant sterol-enriched spread (no NHS subsidy), and for this model a very pessimistic scenario of 5% 
compliance was used [17].  
 
 All analyses were carried out using STATA13 and Microsoft Excel 2013. Half cycle correction was used for 
costs and utilities. Detailed information of model parameters and distribution is shown in Appendix 3.  
 
Results 
Baseline description of study population 
There were 1,598 people with mildly elevated cholesterol (4mmol/l - 6mmol/l) and 640 with high cholesterol 
(above 6mmol/l) in the HSE 2011. The key risk factors are summarised in Table 2. The mean BMI, systolic 
blood pressure, and total cholesterol/HDL cholesterol ratio was higher in the high cholesterol group, which also 
contained a larger proportion of women than the mild cholesterol group. Applying QRISK2, the average 10-year 
CVD risk for the mild cholesterol group is 12.27%, and 12.85% for the high cholesterol group.  
 
<Table 2 about here> 
 
Risks and events avoided 
For both cholesterol groups, the 10-year CVD risks increase with age.  The plant sterol group is associated with 
lower 10-year CVD risks than the normal diet group at all ages (Figure 1).  Regarding relative risks, plant sterol-
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enriched functional foods reduce CVD risk more in men than women, and in older age groups, compared to the 
younger ones (Table 3). 
 
<Figure 1 about here> 
 
<Table 3 about here> 
 
Using deterministic parameters, a diet including the recommended levels of plant sterols avoids 69 CVD events 
(59 non-fatal and 10 fatal CVD events) per 10,000 men and 40 (33 non-fatal and 7 fatal) per 10,000 women, 
aged 45 to 85, at 50% compliance level, and 14 CVD events per 10,000 men and 8 CVD events per 10,000 
women at 10% compliance level.   
 
Cost-effectiveness – base case  
The age- and gender- specific QALYs, costs and ICERs (costs per QALY gained from sterol-enriched spread, 
compared to normal spread) for different cholesterol populations over 20 years at 10% and 50% compliance 
levels, assuming the NHS pays the excess cost of the sterol-enriched product are shown in Table 4. The cost to 
the NHS of subsidising sterol-enriched spread is lower in men because more CVD events are avoided than in 
women. Accordingly QALY gains, which rise with compliance level and age, are also higher for men.  
 
The ICERs (costs per QALY gained) are higher for mildly elevated cholesterol than for the high cholesterol 
group.  Hence subsidising sterol-enriched spread is more cost effective at higher cholesterol levels. In both the 
10% and 50% compliance models, the cost per QALY gained is below the £20,000 threshold for men over 64 
years and women over 74 years with high cholesterol; it is below the £30,000 threshold for men over 54 and 
women over 64 (Table 4).   
 
<Table 4 about here> 
 
The Cost-Effectiveness Acceptability Curves (CEACs) for different age and gender groups at 10% and 50% 
compliance levels for the high and mild cholesterol groups are shown in Figure 2 and 3. For the high cholesterol 
group, when the NHS pays the excess cost, the enriched spread is likely to be cost-effective for men over the 
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age of 64, and women over 74, at the £20,000 threshold, and for men over 54 and women over 64 at the £30,000 
threshold, at both the 10% and 50% compliance levels. For the mild cholesterol group, the probability that plant 
sterol enriched spread is cost effective for any age / gender group, compliance level or threshold is lower than 
for the high cholesterol group. 
 
<Figure 2 about here> 
 
<Figure 3 about here> 
 
Sensitivity analysis 
Using the upper limit (13.3%) of the 95% confidence interval instead of the assumed mean LDL reduction 
(12%) from use of plant sterols, with 50% compliance, and the NHS covering the excess cost, did not affect the 
groups for which enriched spread was cost-effective. However, with the lower limit of the 95% confidence 
interval, the likelihood of plant sterol enriched spread being cost effective is slightly increased for the mild 
cholesterol group (Appendix 4). 
 
We use 10-year time horizon and re-calculate the ICER. We find that plant sterol is cost-effective for female 
above 75 and male above 65 for both groups if the cost-effectiveness threshold is set at £30,000 per QALY 
gained.  
 
When the assumption is adopted that the NHS is responsible for the full costs of providing sterol-enriched 
spread, and the compliance rate is 50%, the plant sterol-enriched diet is only cost-effective for men over 64 with 
high cholesterol and between 75 and 85 with mild cholesterol, and if the cost-effectiveness threshold is set at 
£30,000 per QALY gained. It is not cost-effective for women in any age group, or for either men or women at 
the lower threshold of £20,000 per QALY gained (Appendix 4).  
 
If individuals are assumed to be responsible for the full cost of the sterol-enriched spread, the NHS realises 
savings from reduced treatment costs due to fewer CVD events whilst incurring no charges for the products, 
even at a very pessimistic compliance rate of 5% (Appendix 4).  
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Discussion 
Summary of main findings 
This study is among the first to model CVD outcomes from consumption of plant sterol-enriched foods, and 
appraise cost effectiveness within the British NHS for an adult population with hypercholesterolemia.  Multiple 
scenarios were considered involving varied cost sharing arrangements between the consumer and the NHS (to 
affect consumption), and different assumptions about levels of compliance. Of several sterol-enriched foods 
available, the analysis was based on margarine-type spreads because these are commonly consumed, and an 
efficacious ‘dose’ of sterols is achievable within average daily consumption levels.  Moreover, enriched spread 
is the cheapest means of providing the required intake.  
 
Under the assumption that the difference in cost to the consumer between sterol-enriched and normal spread is 
subsidised, then the sterol-enriched spread is likely to be cost-effective for men with hypercholesterolemia over 
the age of 64, and for women with hypercholesterolemia over 74 years with the compliance level of 10% and 
50% and the cost effectiveness threshold of £30,000 per QALY gained.  At the lower threshold of £20,000 per 
QALY gained, the subsidy is less likely to be cost effective at lower age groups.  Shifting the cost burden of the 
product to consumers increases the likelihood of sterol-enriched spread being a cost effective option. Ultimately, 
if consumers in the target groups bear the full cost, the NHS will maximally benefit from reduced CVD 
treatment costs. The other more costly sterol-enriched products are likely to be less cost-effective for the NHS.  
 
Comparison to other studies  
To date, only three other studies have evaluated the cost-effectiveness of plant sterols [14, 16, 17]. A cost-
benefit analysis of plant sterol-enriched low-fat margarine for cholesterol reduction based on the German 
population found that the 10-year CVD risk and associated costs were significantly lower for the plant sterol 
group compared with the normal diet group. A projection at the level of the German population led to a 
reduction of 117,000 CVD cases over 10 years for the whole German population and a cost saving of €1.3 
billion [14]. Similar results were demonstrated in Canada, where it was estimated that significant savings could   
be made annually for the publicly funded healthcare system if plant sterol-enriched food was approved for sale 
[17].  It has also been suggested that plant sterol-enriched spreads are potentially cost-effective in the prevention 
of CVD risks in adult men and in older women in Finland [16].  
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Limitations of the study 
The results should be interpreted in light of the limitations of the study and the assumptions that were made. 
HSE only covers households in England so findings may not be more widely generalisable.  Compliance levels 
were based on studies from Canada, but these may not reflect the consumption level of plant sterols in England. 
Complicating matters further, the duration of the effects of plant sterols on reduction in LDL-c level is not clear. 
Whilst some studies found that the cholesterol lowering effect is established within a few weeks, and is proved 
to remain stable for at least a year [7, 8, 10], we have assumed a more enduring benefit.  Research also shows 
that doses higher than 3 g/day could lead to negative side effects [8, 38, 39], but evidence on this is limited, and 
no effect has been allowed for. Also, this study does not take account of potentially large inter individual 
variability in absorption and turnover on non-cholesterol sterols that are increasingly under investigation [40]. 
The study primarily adopted the perspective of the NHS. Societal effects associated with CVD are not included 
(productivity loss, family costs, social care). Targeted screening could also affect costs and effectiveness and 
might influence policy decisions. Consideration of these issues, however, would have increased the savings to 
the NHS and made sterol-enriched diets more likely to be cost effective. The data for risk calculations used in 
this study are mainly derived from HSE. However, it was not possible to take account of other lifestyle factors 
that might affect future risks and outcomes (e.g. exercise, health awareness, smoking, alcohol consumption). 
Similarly, it is possible that some subjects in the survey already consume sterols in some form or another, and 
since the extent of this was unknown, it could not be incorporated into the analysis. Also, the time horizon was 
set as 20 years, while QRISK2 is based on the estimation of 10-year risk.  
 
The policy implications of the study  
Pending results from randomised controlled trials, NICE does not recommend routine use of plant sterols and 
stanols for CVD prevention if the patient has already received treatment [25], but focusses instead on promoting 
a more natural cardio-protective diet (low fat and sugar, wholegrains, fruit, vegetables, oily fish, nuts, seeds, 
legumes) and use of statins [41]. Some scholars have pointed out that plant sterols have not been shown to 
reduce clinical end points and suggest that prescription drugs should be preferred to stanol/sterol esters for 
lowering cholesterol except in borderline hypercholesterolemia [42]. Despite this, an increasing number of 
experts and health organisations recommend consuming plant sterols to reduce CVD risks, including the 
American and British Heart Associations [31, 43]. Moreover, the European Commission has acknowledged the 
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value of sterol-enriched foods for cholesterol lowering through approval of health claims on some products [4, 
6].  
 
The findings from this study add weight to calls for the increased use of plant sterol-enriched functional food as 
a preventive strategy for people with hypercholesterolemia, and suggest that encouraging the consumption of 
plant sterol-enriched functional food is likely to bring cost savings to health systems, as well as improving 
patient outcomes. In England, the annual cost of a subsidy equivalent to the excess cost of sterol-enriched spread 
(about £57 per subject in this study) is similar to the annual cost of many statins. A drawback with statins is that 
compliance is reduced because of the varied side effects [44 - 46], and this may be mitigated through use of 
functional foods. Unlike statins, however, which are provided with doctor endorsement and on prescription, 
efforts may be needed to ensure that consumers are aware and motivated to use sterol enriched products and are 
able to understand the claims made on them. Under some circumstances, mass media campaigns may be 
effective, but consideration needs to be given to costs and likely impact in policy deliberations [47].  
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Table 1. Model structure  
Primary events   Secondary events 
From To   From To 
Event free Event free       
  Stable angina   Stable angina Stable angina  
        Unstable angina 
        Non-fatal MI 
        Death 
  Unstable angina   Unstable angina Post-unstable angina 
        Non-fatal MI 
        Death 
  Non-fatal MI   Non-fatal MI Post-non-fatal MI 
        Non-fatal MI 
        Non-fatal stroke 
        Death 
  TIA   TIA Post-TIA 
        Non-fatal MI 
        Non-fatal stroke 
        Death 
  Non-fatal stroke   Non-fatal stroke Post non-fatal stroke 
        Non-fatal MI 
        Non-fatal stroke 
        Death 
  Death       
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Table 2. Baseline characteristics of modelled population by cholesterol level 
  
Mild cholesterol  
population  
(N = 1598) 
High cholesterol  
population  
(N = 640)   
  Mean S.D. Mean S.D.   
Age 59.40 10.42 60.46 9.91   
Proportion of male 0.41 0.49 0.35 0.48   
BMI 27.61 4.95 28.04 4.90   
Systolic blood pressure (mmHg) 129.73 17.41 132.10 17.41   
Total cholesterol (mmol/l)/HDL ratio (mmol/l) 3.98 1.38 4.51 1.53   
10-year CVD risk 12.27 11.87 12.85 10.78   
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 Table 3. RR by risk groups by age and gender 
 
  Mild cholesterol population  High cholesterol population  
  Male Female Male Female 
  Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
45-54 91.29% 0.909,0.917 94.00% 0.938,0.942 89.99% 0.893, 0.907 92.81% 0.923,0.933 
55-64 91.65% 0.913,0.920 93.93% 0.937,0.942 89.90% 0.892, 0.906 93.30% 0.930, 0.936 
65-74 91.90% 0.915,0.923 93.62% 0.934,0.939 91.18% 0.906, 0.918 93.03% 0.927, 0.934 
75-84 92.07% 0.916,0.926 94.00% 0.937,0.943 91.00% 0.900, 0.920 93.42% 0.930, 0.938 
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Table 4. Age – and gender- specific ICERs (£/QALY) over 20 years for mild and high cholesterol groups 
at 10% and 50% compliance levels: main analysis in which NHS pays excess cost of sterol enriched 
spread  
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 Plant sterol enriched spread cost effective at NICE threshold below £30,000 per QALY gained 
 Plant sterol enriched spread cost effective at NICE threshold below £20,000 per QALY gained 
 
Incremental QALYs show QALY gained from sterol enriched spread, compared to no sterol enriched spread 
Incremental costs show the cost to the NHS of sterol enriched spread, less treatment cost savings from reduced 
CVD events 
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Figure 1.  10-year CVD risk for the mild and high cholesterol groups for the normal diet and plant sterol 
groups by age and gender 
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Figure 2. Cost-effectiveness acceptability curves at 10% compliance level (mild and high cholesterol population): main analysis in which NHS pays excess cost of 
sterol enriched spread  
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
60
00
70
00
80
00
90
00
10
00
0
11
00
0
12
00
0
13
00
0
14
00
0
15
00
0
16
00
0
17
00
0
18
00
0
19
00
0
20
00
0
22
00
0
24
00
0
26
00
0
28
00
0
30
00
0
32
00
0
34
00
0
36
00
0
38
00
0
40
00
0
50
00
0
60
00
0
70
00
0
80
00
0
90
00
0
10
00
0
0
12
00
0
0
14
00
0
0
16
00
0
0
18
00
0
0
20
00
0
0
22
00
0
0
Male 45-54 Male 55-64 Male 65-74 Male 75-84 Female 45-54 Female 55-64 Female 65-74 Female 75-84
Value of threhold ratio (£)
P
ro
b
ab
ili
ty
 o
f c
o
st
-e
ff
ec
ti
ve
ne
ss
, %
 (H
ig
h
 c
h
o
le
st
er
o
l)
 26 
 
Figure 3. Cost-effectiveness acceptability curves at 50% compliance level (mild and high cholesterol population): main analysis in which NHS pays excess cost of 
sterol enriched spread                                  
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Appendix 1. Cost and health utility values for health states 
Health states 
Costs 
(£) 
Source Utility Source 
EF 0 Ara, Tumur et al. 2008 
1.060-
0.004*age 
Ara, Tumur et al. 2008 
Angina first year 684.00 
NHS reference costs 
2013/14  
0.808  Lenzen, Scholte op Reimer 
et al. 2006, Ara, Tumur et al. 
2008 
Angina 
subsequent years 
233.00 
Ara, Tumur et al. 2008 
(Inflated to 2015)  
0.9 
Unstable angina 
first year 
1428.50 
NHS reference costs 
2013/14  
0.731 
 Goodacre, Nicholl et al. 
2004, Kim, Henderson et al. 
2005 
  
Unstable angina 
subsequent years 
233.00 
 Ara, Tumur et al. 2008 
(Inflated to 2015) 
0.8 
MI first year 1377.00 
NHS reference costs 
2013/14 
0.7 Goodacre, Nicholl et al. 2004, 
Lacey, Walters 2003 
MI subsequent 
years 
233.00 
Clarke et al., 2003155 
(inflated to 2015) 
0.8 
TIA 1419.00 
NHS reference costs 
2013/14  
1.060-
0.004*age 
 Aprile, Di Stasio et al. 2006, 
Ara, Tumur et al. 2008 
  
TIA subsequent 
years 
373.00 
 Ara, Tumur et al. 2008 
(Inflated to 2015) 
1.060-
0.004*age 
Stroke 4843.00 
NHS reference costs 
2013/14 
0.5 Tengs, Lin 2003, van Exel, N. 
J. A., Reimer et al. 2004, 
Leeds, Meara et al. 2004 
Stroke 
subsequent years 
3055.00 
Youman, Wilson et al. 2003 
(Inflated to 2015) 
0.629 
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Appendix 2. Calculation of the food costs  
Functional food 
Unit cost 
(£) 
Plant sterols 
Annual cost 
(£) 
Plant sterol yoghurt drink 6*67.5G (manufacturer 
brand) 
3.78 2g per bottle 460.2 
Plant sterol yoghurt mini drink 6*100ml 
(manufacturer brand) 
3.5 2g per bottle 426.13 
Plant sterol Milk 1L (manufacturer brand) 1.39 3g per 1L mil2l 507.7 
Plant sterol Light Spread 250G (manufacturer brand) 1.9 
18.75g per 250G 
spread 
111.04 
Non sterol enriched spread 500G (supermarket own 
brand) 
1.85 N/A 54.1 
Note: the calculation of annual cost is based on 3g/day intake and 365.25 days per year. One unit (bottle) of 
plant sterol yohgurt drink contains 2g plant sterols, so the daily cost is based on a consumption of 2 units. There 
are currently two plant sterol enriched spreads available in the UK, and costs were based on the leading brand.  
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Appendix 3. Parameters and distributions 
  Base-line value Distribu
tion 
Source 
Annual CVD 
risks 
Derived from HSE 2011 using 
QRISK2 function 
Log-
normal 
Authors' own 
RR Age- and gender- specific RR  Log-
normal 
Authors' own 
Transition 
probabilities  
Age- and gender- specific 
transition probabilities 
Beta Derived from Ward S. et al.  
Costs of health 
states 
Cost for the first year and 
subsequent year of each health 
state was allowed  
Gamma First year costs were derived from NHS 
reference costs. Subsequent year costs 
were derived from Ward S. et al.   
Costs of the 
functional food 
Supermarket price in April. 
2014 
Determi
nistic 
Derived from supermarket websites in 
April 2014 
Utility of health 
states 
Utilities of the first year and 
subsequent year of each health 
state was used in the analysis 
Beta Derived from Ara R et al., Ward S et al., 
D’Agostino RB et al., Goodacre S. et al., 
Lensen M et al., Kim J. et al., Lacey EA et 
al  
Compliance level Varying compliance level at 
50% and 100% for the main 
analysis.  
Beta Derived from National Diet and Nutrition 
Survey  
Discount rate 3.5% for both cost and utility Determi
nistic 
 Derived from NICE technology appraisals 
methods guide 2013 
Note: parameter distributions are consistent with Briggs et al. 2014 
  
 30 
 
Appendix 4. ICER (£/QALY): Results of sensitivity analyses 
  Mild cholesterol population  High cholesterol population 
  Male Female Male Female 
NHS pays the cost difference between sterol enriched and normal spread  
50% compliance level 
LDL reduction at 10.7%       
45-54 75009.93 251029.38 47023.289 149367.506 
55-64 41170.06 117946.26 24539.187 77118.267 
65-74 21675.50 37354.67 14832.649 25045.405 
75-84 18506.26 25913.87 13069.377 18724.213 
LDL reduction at 13.3%       
45-54 64061.41 200643.05 40957.433 123877.587 
55-64 34767.54 94212.97 21297.750 62882.757 
65-74 18096.92 29982.24 12547.142 20458.145 
75-84 15297.62 20403.12 11015.281 15031.192 
NHS pays the cost difference between sterol enriched and normal spread  
50% compliance level 
Time horizon as 10 year  
45-54 144664.38 481921.45 98721.807 304097.157 
55-64 73227.38 231149.10 46967.747 158458.671 
65-74 36043.75 70154.82 25600.421 48643.878 
75-84 19820.82 30012.02 13320.681 20488.245 
NHS pays the full cost of the plant sterol enriched spread 
50% compliance level       
45-54 100647.60 319903.54 87353.73 266372.54 
55-64 56404.55 151715.76 46316.86 137274.50 
65-74 30694.44 49699.46 28073.40 45374.08 
75-84 28986.28 37536.59 25318.37 34101.58 
Individual pays the full cost of the plant sterol enriched spread 
5% compliance level       
45-54 -2032.06 -2311.43 -2032.08 -2311.44 
55-64 -1892.32 -2219.71 -1892.37 -2219.72 
65-74 -1593.21 -1486.11 -1593.25 -1486.13 
75-84 -2002.72 -1573.18 -2002.83 -1573.21 
 
 
  Plant sterol enriched spread cost effective at NICE threshold below £30,000 per QALY gained 
  Plant sterol enriched spread cost effective at NICE threshold below £20,000 per QALY gained 
 
 
 
